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Abstract: BACKGROUND AND AIMS The optimal timing of treatment escalation in Crohn’s disease
[CD] remains a challenging issue, and very little is known about its long-term development following
early versus late administration of anti-TNF antibodies. The long-term outcome of Swiss CD patients
was comparatively assessed in an up to 10-year follow-up, using patients participating in the Swiss In-
flammatory Bowel Disease Cohort Study [SIBDCS]. METHODS Prospectively collected SIBDCS patient
data, including disease history, baseline characteristics at enrolment, and course of disease, were analysed
in patients with early versus late [<24 versus ฀24 months after diagnosis] and no anti-TNF treatment.
RESULTS A reduced risk of developing bowel stenosis was found in patients who received early anti-TNF
treatment. This association was seen in patients overall and also in the subgroups of CD patients with-
out pre-existing complications [Log-rank test: p < 0.001].Furthermore, osteoporosis and anaemia were
observed significantly less frequently in patients who received early anti-TNF treatment, compared with
either patients who received treatment late [p < 0.001 and p = 0.046, respectively] or were never [p <
0.001 for both] treated with anti-TNF antibodies. Patients with early anti-TNF administration sought
medical consultations significantly less often, including gastroenterologists in private practice [p = 0.017],
ambulatory [outpatient] hospital visits [p = 0.038], and a composite of any medical visits [p = 0.001].
The percentage of patients unable to work was lowest for early-anti-TNF-treated patients, in comparison
with patients who were treated late or never [3.6% vs 8.8% vs 3.7%, p = 0.016]. CONCLUSIONS In
CD patients within the SIBDCS, early anti-TNF administration was found to be associated with several
indicators of a more favourable long-term outcome.
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EARLY INITIATION OF ANTI-TNF IS ASSOCIATED WITH 1 
FAVOURABLE LONG-TERM OUTCOME IN CROHN’S DISEASE: 2 
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Background and Aims  29 The optimal timing of treatment escalation in Crohn’s disease (CD) remains a challenge 30 
and very little is known on the long-term evolution in early versus late administration 31 
of anti-TNF antibodies. We comparatively assessed the long-term outcome in Swiss CD 32 
patients with an up to 10-year follow-up using patients participating in the Swiss 33 
Inflammatory Bowel Disease Cohort Study (SIBDCS). 34 
 35 
Methods 36 
Prospectively-collected SIBDCS patient data, including disease history, baseline 37 
characteristics at enrolment and course of disease were analysed in patients with early 38 
versus late (<24 versus >=24 months after diagnosis) and no anti-TNF treatment. 39 
 40 
Results 41 
We found a reduced risk of developing bowel stenosis in early anti-TNF treated 42 
patients. This association was seen in patients overall and in the subgroups of CD 43 
patients without pre-existing complications (Log-rank test: p<0.001).  44 
Further, osteoporosis and anaemia were observed significantly less frequently in early 45 
anti-TNF treated patients, compared to both, patients late (p<0.001 and p=0.046, 46 
respectively) or never (p<0.001 for both) treated with anti-TNF antibodies. Patients 47 
with early anti-TNF administration were significantly less often seeking medical 48 
consultation, including a gastroenterologist in private practice (p=0.017), ambulatory 49 
(outpatient) hospital visits (p=0.038) and a composite of any medical visits (p=0.001). 50 
Percentages of patients unable to work during the last 3 months were lowest in early 51 
anti-TNF treated patients in comparison to patients who were treated late or never 52 
with anti-TNF agents (3.6% versus 8.8% versus 3.7%, p=0.016). 53 
 54 
Conclusions 55 
We identified early anti-TNF administration to be associated with several indicators of a 56 
more favourable long-term outcome in CD patients within the SIBDCS. 57 
Key words 58 
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The optimal management of patients suffering from chronic inflammatory illnesses like 63 
Crohn’s disease (CD) has not been clarified and remains a matter of ongoing research. A 64 
major challenge lies in the prediction of the future disease course which is difficult or even 65 
impossible, according to the tools currently available in clinical practice [1].  66 
An important breakthrough in CD therapy however was the approval of anti-tumor 67 
necrosis factor (TNF) drugs in 1998 [2].  68 
The substantial value of anti-TNF drugs was soon realized and new possibilities of disease 69 
control seemed achievable. Strong anti-inflammatory activity of TNF inhibitors enabled a 70 ‘treating patients to target’ approach, aiming at complete control of inflammation beyond 71 
mere symptom surveillance and clinical remission [3]. Even in the nearer future 72 
individualised therapies might be state of the art. A potentially beneficial impact of anti-73 
TNF drugs on the evolution of disease course was indicated in animal [4] as well as cohort 74 
studies in humans [5-7]. 75 
Besides that, several studies have compared a ‘step-up’ with a ‘top-down’ treatment 76 
strategy in CD [8-10]. Current literature favours a ‘rapid step-up’ strategy with stepwise 77 
early introduction of immunosuppressive agents (IM) and timely addition of anti-TNF 78 
[11-14], although the benefit of early IM remains controversial [13, 15]. The impact of a 79 ‘top-down’ strategy with early introduction of anti-TNF has been investigated by even 80 
more studies [4, 16-25], including the key question, whether the disease course may be 81 
modified through early anti-TNF administration [4].  82 
However, the evidence of a potentially beneficial impact on the disease course and our 83 
knowledge on proper selection of patients in need of an early aggressive treatment 84 
remains limited. Specifically, the long-term evolution of disease beyond the usual 85 
observation periods of one year in most studies and 5 years in very few instances remains 86 
unknown. 87 
Using the prospectively obtained data from patients participating in the SIBDCS we aimed 88 
to investigate, if early anti-TNF administration, defined as initiation during the first 24 89 
months after CD diagnosis, is associated with beneficial effects on predefined outcome 90 
parameters in CD, compared to either patients with initiation of anti-TNF beyond the first 91 
24 months since diagnosis or without anti-TNF treatment. 92 





Materials and Methods 94 
 95 
Study Population: 96 
In 2006 the nationwide inclusion of IBD patients into the SIBDCS started. The SIBDCS was 97 
designed as a prospective cohort study. At enrolment, all patients provided written 98 
informed consent for participation in the study. SIBDCS receives ongoing supporting 99 
grants from the Swiss National Science Foundation (SNSF) and has been approved by the 100 
local ethical committees of all participating centres. SIBDCS has been described in detail 101 
by Pittet et al. [26, 27]. 102 
At time of inclusion, patients as well as the treating physicians filled out enrolment 103 
questionnaires. Patient questionnaires covered questions about the individual perception 104 
of the clinical disease course, the severity of symptoms as well as quality of life (QoL) and 105 
socioeconomic associations. Physicians questionnaires focused on clinical characteristics, 106 
classification and course of IBD. Patients as well as treating physicians are followed up 107 
annually by follow-up (fu) questionnaires similar to the original inclusion questionnaires. 108 
Data of all CD patients enrolled into SIBDCS since its start in 2006 have been used for the 109 
analysis of our study. Data extraction from the SIBDCS data base as well as the following 110 
statistical analysis were performed by the SIBDCS data centre in Lausanne, Switzerland.  111 
 112 
Data extractions, definitions:  113 
All data were collected prospectively through the SIBDCS cohort study and analysed 114 
retrospectively at the cut-off date 12/31/2016 for our study. Anti-TNF medication was 115 
defined as an administration of at least one dose of the three anti-TNF agents currently 116 
approved for treatment of CD in Switzerland, i.e. infliximab, adalimumab or certolizumab 117 
pegol during the observation period. 118 
To assess the impact of timing of anti-TNF administration on the disease course, we 119 
defined three groups: ‘early anti-TNF’, i.e. patients having received anti-TNF within the 120 
first 24 months since diagnosis;  ‘late anti-TNF’, i.e. patients having received anti-TNF 121 
medication after 24 months since diagnosis and ‘no anti-TNF’, i.e. patients who have never 122 
received anti-TNF therapy since IBD diagnosis within the observation time. 123 
Primary outcomes of our study included bowel stenosis, perianal fistula, other fistula, any 124 
fistula, perianal surgery, intestinal surgery, any surgery and extraintestinal 125 





looking at time to first complication. ‘Secondary outcomes included the occurrence of 127 
osteoporosis and anaemia, utilization of health care resources and inability to work 128 
because of CD (absence from work due to other reasons was not included in these 129 
analysis). Within secondary outcomes the rates of occurrence between different 130 
treatment groups were compared.  131 
Safety data included rates and differences in occurrence of colorectal cancer (CRC), 132 
intestinal lymphomas (IL) and deaths. Additionally, the rates of opportunistic infections 133 
which led to anti-TNF therapy cessation were also assessed. 134 
In the survival analysis of the primary outcomes, patients who were treated early (<24 135 
months), were compared with patients who were treated late (>=24 months) with anti-136 
TNF agents. Pre-existing complications were defined as any single or more of the same 137 
complications, which were analysed as primary outcomes during follow-up after anti-TNF 138 
induction, existing already prior to anti-TNF induction. 139 
To define bowel stenosis, there is a lack of standardized definitions, which has been aimed 140 
at overcoming by a very recent expert consensus, according to which the best current 141 
definition for a small bowel stricture is based on a combination of wall thickening, luminal 142 
narrowing and pre-stenotic dilation [28]. Assessing these parameters, the diagnosis of 143 
bowel stenosis in our study was derived by the examination of clinical symptoms and 144 
signs, radiological examinations and endoscopy. 145 ‘Perianal fistula’ refers to any kind of fistula located in the perianal area, such as 146 
submucosal, intersphincteric, transsphincteric, suprasphincteric or extrasphincteric 147 
fistulas. ‘Other fistula’ refers to any kind of non-perianal fistula, whereas ‘any fistula’ 148 
combines perianal as well as any kind of non-perianal fistula. Likewise, ‘perianal surgery’ 149 
refers to perianal surgical procedures, such as drainage of perianal abscesses, seton-150 
placement or any form of fistula extraction/closure procedure, whereas ‘intestinal 151 surgery’ refers to any kind of surgery performed at the intestine related to CD, including 152 
any kind of resection or ostomy surgery. Again ‘any surgery’ refers to the need for any 153 
surgery in relation to CD, irrespective of location or type of procedure.  154 
EIM includes peripheral arthritis/arthralgia, uveitis/iritis, pyoderma gangrenosum, 155 
erythema nodosum, aphthous oral ulcers/stomatitis, ankylosing spondylitis (Bechterew), 156 
sacroiliitis and primary sclerosing cholangitis.  157 
In terms of complications we assessed osteoporosis and anaemia due to their clinical 158 





Further, we tested for differences in the utilization of health care resources across 160 
treatment groups. We therefore assessed medical visits related to CD at general 161 
practitioners, gastroenterologists in private practice, ambulatory visits at hospitals and 162 
hospitalizations. The category ‘other’ includes medical visits at any physician not falling 163 
into the predefined categories above, for example specialised surgeons like 164 
coloproctologists. With every patient questionnaire, the data on utilization of health care 165 
resources was collected regarding the respective last 3 months of each annual follow-up 166 
questionnaire. The recall period of 3 months was chosen in cooperation with experts in 167 
public health and psychologists, which were involved in the SIBDCS from the very 168 
beginning until now. By using a longer recall period however, the risk of recall bias and 169 
inadequate data considerably increases. 170 
Similar to the data on utilization of health care resources, data on work ability was also 171 
assessed with every annual patient questionnaire regarding the last 3 months since the 172 
last follow-up patient questionnaire within the cohort. 173 
 174 
Statistical Analysis 175 
All statistical analyses were carried out using the Stata Software (v. 14.2, StataCorp, 176 
College Station, TX, USA). 177 
Categorical data were summarized as raw frequencies and relative percentages. 178 
Differences in categorical data distribution between two or more independent groups 179 
were assessed using the chi-squared test, or the Fisher’s exact test in case of low sample 180 
size. 181 
Continuous data distribution was assessed using normal quantile-quantile (QQ)-plots. 182 
Gaussian distributed data were summarized as mean, standard deviation (SD) and range, 183 
while non-Gaussian distributed data were summarized as median, interquartile range 184 
(IQR) and range. Differences in means for Gaussian distributed data between two 185 independent groups were assessed using the Student’s t-test, or ANOVA for more than 186 
two independent groups. Differences in distribution for non-Gaussian distributed data 187 
between two independent groups were assessed using the Wilcoxon-Mann-Whitney rank 188 
sum test, or the Kruskall-Wallis test for more than two groups. 189 
The primary outcomes were analysed as time-to-event data. Complication-free 190 





log-rank test was used to assess overall differences between survival curves for 192 
independent groups. 193 
A p-value <= 0.05 was considered as statistically significant.  194 







Study population 198 
Within the ten-year timespan from the start of patients’ inclusion into SIBDCS in early 199 
2006 until the 31st of December 2016 a total of 1707 adult CD patients were enrolled and 200 
1592 patients could be analysed (Figure 1). Demographic data and clinical characteristics 201 
of the study population are shown in Table 1. 202 
Of note, patients with early anti-TNF therapy had a younger age (median age 32 years vs. 203 
44 years and 48 years, in late and no anti-TNF, respectively, p< 0.001) and shorter disease 204 
duration at the time of inclusion into our study, with a higher fraction of B1p phenotype.  205 
Looking at complications, patients without a given pre-existing complication prior to anti-206 
TNF induction had a younger age, shorter disease duration and lower rate of other 207 
complications compared to their counterparts with the respective pre-existing 208 
complication. 209 
Regarding perianal surgery however, there was no significant difference in age between 210 
patients with or without perianal surgery prior to anti-TNF induction (p=0.067). Also, 211 
there were no significant differences in the presence of complications other than EIM 212 
between patients with or without EIM manifestation prior to anti-TNF induction 213 
(p=0.084). 214 
 215 
Disease course and complications 216 
 217 
Bowel stenosis 218 
We found a reduced risk of developing stenosis in early anti-TNF treated patients 219 
compared to late anti-TNF treated patients, using Kaplan-Meier analysis as shown in 220 
Figure 2 (log-rank test: p<0.001). This difference was most pronounced in the subgroups 221 
of CD patients without pre-existing complication (log-rank test: p<0.001), whilst only by 222 
trend in patients with pre-existing complication (p=0.147, Table 2). A significant 223 
difference between early and late anti-TNF treated patients was also detected without 224 
considering pre-existing complications (p<0.001, Supplementary Table 1). 225 
Amongst patients without pre-existing complication of bowel stenosis a larger number of 226 
early anti-TNF treated patients were free from bowel stenosis 2, 5 and 10 years after anti-227 
TNF initiation (95.1%, 83.6% and 67.8%, respectively), than late anti-TNF treated 228 






Penetrating complications and surgery 231 
Although we observed a global difference in need of perianal surgery across the patient 232 
groups overall (p=0.002, Table 2), this difference was predominantly seen between 233 
patients with versus without pre-existing complication and not according to early versus 234 
late anti-TNF treatment (Supplementary Figure 1).  235 
In addition, there were no significant differences favouring early intervention neither 236 
regarding intestinal or perianal surgery nor occurrence of perianal fistula or fistula 237 
overall (Table 2). 238 
Amongst patients without pre-existing complication of any penetrating complication or 239 
surgery a larger number of early anti-TNF treated patients were free from penetrating 240 
complications and surgeries 10 years after anti-TNF initiation (60.1%, 68.2%, 70.8% and 241 
83.4%, respectively), than late anti-TNF treated patients (50.7%, 63.6%, 57.2% and 242 
75.6%, Supplementary Table 2). 243 
 244 
Extraintestinal manifestations 245 
We observed no difference in the development of EIM in early versus late anti-TNF treated 246 
patients without pre-existing complication (Supplementary Figure 2). However, early 247 
treated patients with pre-existing complication appeared to develop less EIM by trend 248 
(p=0.087, Table 2). 249 
Looking at pre-existing complication of EIM a larger number of early anti-TNF treated 250 
patients were free from EIM 2, 5 and 10 years after anti-TNF initiation (75.0%, 49.8% and 251 
26.3%, respectively) than late anti-TNF treated patients (74.7%, 46.8% and 22.1%, 252 
Supplementary Table 2). 253 
 254 
Osteoporosis and anaemia 255 
Osteoporosis and anaemia were observed significantly less frequently in early versus late 256 
anti-TNF treated patients (p<0.001 and p=0.046, respectively, Supplementary Table 3, 257 
Figure 3).  258 
 259 
Medical consultations and hospitalizations 260 
Patients with early anti-TNF administration were significantly less often in need for 261 
medical consultations, including consultations with a gastroenterologist in private 262 





medical visits at all (p=0.001). There was, however, no difference in visits to a general 264 
practitioner or any other CD related medical visits.  265 
Overall hospitalizations between the three tested groups differed with the lowest number 266 
of hospitalizations in the group of patients never treated with anti-TNF (p=0.001, 267 
Supplementary Table 4). However, there was no difference between patients with early 268 
vs. late anti-TNF administration (Figure 4) regarding hospitalization rates.  269 
 270 
Absence from work 271 
TNF treatment influenced work disability due to CD across all treatment groups (p=0.016, 272 
Supplementary Table 5). Early treated patients were by trend less likely to be unable to 273 
work with 3.6% of patients absent from work compared to 8.8% in late treated patients 274 
(p=0.096, Supplementary Table 5, Figure 5). 275 
 276 
Safety 277 
There were no significant differences in CRC or IL between the three different treatment 278 
groups (Supplementary Table 6). The absolute number of patients observed regarding 279 
opportunistic infection leading to therapy cessation was very low with 1 patient (0.4%) 280 
within the early and 4 patients (0.6%) within the late treatment group (Supplementary 281 
Figure 3). 282 






In this study we demonstrated an association of early anti-TNF administration with 285 
reduced risk of developing bowel stenosis. In addition, patients with any pre-existing 286 
complication were relatively protected from a recurrence of this respective outcome 5 287 
and 10 years after early vs. late anti-TNF initiation. 288 
Specifically, osteoporosis and anaemia were less frequently observed in the group of 289 
patients with early anti-TNF treatment. Furthermore, patients with early anti-TNF 290 
administration were less frequently seeking medical consultation and by trend showed 291 
lower rates of absence from work due to CD compared to patients with late anti-TNF 292 
administration. 293 
In terms of stricturing disease behaviour, our findings are in line with a previous study 294 
from SIBDCS, where a significant association between IM or anti-TNF agents and reduced 295 
bowel stenosis was observed [16].  296 
Besides such a preventive effect, anti-TNF agents might also be effective in patients with 297 
established fibrotic disease. This has previously been suggested in a study by Allocca et 298 
al. [29] in stricturing CD, showing that anti-TNF agents may prevent surgery in up to two-299 
thirds of patients with intestinal stenosis. Beneficial effects of early anti-TNF 300 
administration seem to be selective for bowel stenosis since our study and previous 301 
investigations did not identify any effects on the overall need for surgery in CD [30-32].  302 
The reason for stricturing disease to be more prone to be modulated by early anti-TNF 303 
administration in our study as compared to penetrating disease remains both unclear and 304 
also controversial. Some of recently published other studies on this topic also indicated 305 
the opposite, showing that anti-TNF therapy might prevent the development of 306 
penetrating (B3) but not stricturing (B2) disease migration [33-35].  307 
A possible explanation for our findings might be that bowel stenosis and scar tissue 308 
formation reflect the result of a long-term cumulative effect of continuous inflammation. 309 
Stopping or attenuation of inflammation at an early stage might therefore prevent the 310 
ongoing progression of scar tissue formation, wall thickening, luminal narrowing and thus 311 
evolution of stenosis over time [36-38]. In contrast, penetrating disease might manifest 312 
more suddenly at any time of the disease course [39], turning it out to be less susceptible 313 
to modification by early anti-TNF treatment. 314 
According to our results, the overall need for surgery doesn’t seem to be affected by the 315 





that an early use of anti-TNF can positively affect symptoms of stenosis but might not yet 317 
be, even though risk factors can be identified[41], an appropriate strategy to reduce 318 
surgical interventions [31, 32, 42, 43]. 319 
In contrast to this, a retrospective analysis among Korean CD patients found significantly 320 
longer times to intestinal surgery (p< 0.001), stricturing complications (p= 0.002), and 321 
penetrating complications (p< 0.001) in the early anti-TNF/ IM groups compared to the 322 
late treatment group (47). 323 
The development of EIM does not seem to be affected by the point of time of anti-TNF 324 
administration. Also, pre-existing EIM does not seem to be affected differently by early or 325 
late anti-TNF intervention. 326 
There are, however, studies on EIM and IBD phenotypes and medication also including 327 
studies within the SIBDCS indicating that the presence of EIM is often associated with 328 
active disease, positive family history or treatment strategy (higher AZA exposure) [44, 329 
45]. Nonetheless, to the best of our knowledge there are no studies addressing the best 330 
point of time of anti-TNF administration regarding evolution of EIM.  331 
In our study early anti-TNF administration was associated with a lower risk of 332 
osteoporosis which remains a frequent problem in IBD patients [46]. Previously, 333 
infliximab therapy has been associated with increased biochemical markers of bone 334 
formation without increasing bone resorption [47]. Whether this may be due to a direct 335 
beneficial effect of TNF blockade on bone turnover, a beneficial effect on CD activity 336 
resulting in decreased glucocorticoid exposure or both remains difficult to determine, 337 
even more so as osteoporosis was not the primary outcome of this study.  338 
We found early anti-TNF administration to be associated with a lower risk of anaemia. 339 
Short-term anti-TNF therapy may significantly improve iron metabolism and, 340 
subsequently, anaemia in IBD [48]. This effect appears to be primarily related to the 341 
modulation of the cytokine network, leading to a relevant decrease of hepcidin, a master 342 
regulator of anaemia of chronic disease. On the other hand, during long-term treatment 343 
anti-TNF therapy might also improve iron deficiency anaemia through the induction of 344 
mucosal healing.  345 
We identified a lower need for consultations at gastroenterologists in private practice and 346 
outpatient visits at hospitals in the early treatment group but not in hospitalization rates 347 
and consultations of general practitioners. In a systemic review [49] assessing reduction 348 





anti-TNF agents reduced the odds of hospitalization by half. Even more encouraging are 350 
the results of another investigation, revealing an association of timely anti-TNF 351 
administration and decrease in hospitalization rates [20].  352 
There are only few studies investigating absence from work due to CD in relation to 353 
medical therapy [50-55] and to the best of our knowledge, no study so far addressed 354 
effects of timing of anti-TNF on CD-related work disability. We showed significantly lower 355 
rates of absence from work amongst early anti-TNF treated CD patients compared to late 356 
treated patients and even slightly lower rates of work disability compared to patients 357 
never having been treated with anti-TNF. 358 
With the increase in availability of newer agents to treat IBD, the question of positioning 359 
and determination of the best timepoint in the course of the individual patient’s disease 360 
is getting more imminent. Beyond anti-TNF a multicentre open-label phase IV trial (LOVE-361 
CD; NCT02646683) is currently recruiting patients with CD, aiming to investigate 362 
whether clinical and endoscopic remission at week 26 (1°EP) is different between 363 
patients with early (<24months after diagnosis) vs. late primary administration of 364 
vedolizumab. Similar studies also looking at complications rates are desirable for other 365 
newer agents, including ustekinumab and JAK-inhibitors. 366 
Our study has several strengths and limitations. As a limitation, CD patients from tertiary 367 
care hospitals are over-represented within SIBDCS and the patient population of the 368 
SIBDCS cannot be considered fully population-based with a presumable preponderance 369 
of patients with more severe disease. Moreover, data acquired by questionnaires may be 370 
linked with a risk of bias, above all reporting and recall biases. Further, there are no 371 
detailed data available on individual doses and time intervals of anti-TNF administration. 372 
The patient numbers in some of our analysed subgroups remain rather small. This 373 
specifically applies for patients with early anti-TNF intervention and pre-existing 374 
complication of the respective outcome parameter. Nevertheless, those patient groups 375 
were still kept in the analysis as we think they provide interesting information. Overall, 376 
we must underline that our investigation may not be sufficiently powered to draw any 377 
robust conclusions with regards to the risk benefit balance of early anti-TNF 378 
administration. In terms of risks, severe adverse events (e.g. major infections requiring 379 
ICU or melanoma) have a tremendous impact but are fortunately infrequent. Due to the 380 
latter, larger study population or large (multinational) patient registries are 381 





speculate about underlying causes and effects. For definite answers, prospective 383 
randomized long-term studies would be needed. However, such trials are virtually 384 
impossible to perform. Therefore, prospective cohort studies are adequate means to 385 
address the potential impact of early anti-TNF administration on the course of disease 386 
and the rigorous annual follow-up with detailed physician and patient questionnaires 387 
represent a strength of our study. In addition, the long prospective follow-up period of up 388 
to 10 years represents another important strength.  389 
Furthermore, our study may even have underestimated the benefit of early anti-TNF 390 
administration since patients in the no anti-TNF group might be positively selected for a 391 
less severe disease course (as indicated by several outcome parameters with apparent 392 
beneficial results in this group including Crohn’s Disease Activity Index (CDAI) score, 393 
rates of hospitalization, perianal fistula formation and perianal surgery). In view of this, 394 
the reduction of bowel stenosis, lower rates of osteoporosis and anaemia, absence from 395 
work due to CD and ambulatory hospital visits in the early treatment group shown by our 396 
study indicate a true beneficial effect.  397 
Importantly, one of the biggest risk factors for the development of any complication 398 
appeared to be a prior history of the very same complication. Considering this factor, we 399 
compared patients with or without a history of the respective complication separately in 400 
our survival analysis to distinguish the different preconditions in time to event.  401 
In conclusion, we observed an association between early anti-TNF administration and 402 
several beneficial clinical outcomes in CD, including a reduced risk of bowel stenosis, 403 
osteoporosis and anaemia. Additionally, we observed lower rates of medical 404 
consultations and absence from work due to CD upon early anti-TNF treatment. 405 
Accordingly, patients with a stricturing type (B2) or at risk to develop such a phenotype 406 
(i.e. those with long-segment or multi-segmental small bowel inflammatory lesions) 407 
might benefit most from an early anti-TNF intervention. Our results thus highlight the 408 
importance of a proper identification of patients in need of early anti-TNF administration, 409 
which currently remains a big challenge for the practicing clinician in the absence of high-410 
accuracy tools to predict future course of CD. 411 
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Figure 1: Flowchart Study Population 614 






Figure 2: Kaplan–Meier curves showing freedom from developing new bowel stenosis in 617 
patients treated early with anti- TNF agents compared to patients treated late with anti- 618 
TNF agents, with or without history of previous bowel stenosis 619 






Figure 3: Frequency of osteoporosis and anaemia among the different treatment groups. 622 
CI: confidence interval 623 






Figure 4: Frequency of patients with medical visits and hospitalizations related to IBD 626 
among the different treatment groups 627 
CI: confidence interval 628 






Figure 5: Percentages of patients with absence from work among the three different 631 
treatment groups 632 
CI: confidence interval 633 
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Table 1: Baseline characteristics and demographic data of study population.  637 
IQR: interquartile range 638 







Table 2: P-values of primary outcomes using Log-rank tests and Kaplan-Meier analysis  642 





Early – no pre-existing c.  
vs 
Early – pre-existing c. 
vs 
Late – no pre-existing c. vs 

















pre-existing complication  
Stenosis <0.001 <0.001 0.147 
Perianal fistula 0.506 0.671 0.560 
Other fistula 0.961 0.781 0.676 
Any fistula 0.627 0.413 0.519 
Perianal 
surgery 









Any surgery 0.927 0.702 0.892 






Online Supplementary Figures and Tables 645 
 646 
Supplementary Figures  647 
 648 
 649 
Supplementary Figure 1: Kaplan–Meier curves showing no benefit in the need of new 650 
perianal surgery in patients treated early with anti- TNF agents compared to patients 651 
treated late, with or without history of previous perianal surgeries 652 






Supplementary Figure 2: Kaplan–Meier curves showing no differences in development of 655 
EIM in patients treated early with anti- TNF agents compared to patients treated late with 656 
anti- TNF agents, with or without history of pre-existing EIM 657 






Supplementary Figure 3: Percentages of opportunistic infections which led to anti-TNF 660 
therapy cessation between early and late treatment groups  661 
CI: confidence interval 662 





Supplementary Tables  664 





Early treated -  
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complication  
Early treated -  
pre-existing 
complication  
Late treated -  
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complication  





  2 years 
  5 years 























  2 years 
  5 years 























  2 years 
  5 years 























  2 years 
  5 years 























  2 years 
  5 years 























  2 years 
  5 years 





















Supplementary Table 2: Percentage of patients with 95% confidence intervals free from 668 






Primary outcome Parameters 
Comparison 




Perianal fistula 0.524 
Other fistula 0.742 
Any fistula 0.331 
Bowel Stenosis <0.001 
Intestinal surgery 0.201 
Fistula/Abscess surgery 0.698 






Supplementary Table 3: Rates and differences of osteoporosis and anaemia between 672 
treatment groups 673 
 674 
Supplementary Table 4: Medical visits and hospitalizations during the last 3 months 675 
 676 
Supplementary Table 5: Absence from work of CD patients during the last 3 months 677 
 678 









early vs late 
  Colorectal cancer (CRC) 











Supplementary Table 6: Rates and differences of CRC and IL between treatment groups 679 
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3 months 
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during last 3 months 
  No 
  Yes 
 
 
107 (96.4) 
4 (3.6) 
 
 
310 (91.2) 
30 (8.8) 
 
 
311 (96.3) 
12 (3.7) 
 
 
 
0.016 
 
 
 
0.096 
